PRJNA268221
Screening of TNFRSF13B in a group of CVID and healthy controls in Sri Lanka
CVID is the commonest clinically relevant primary immune deficiency with an estimated prevalence of 1 in 10,000 to 1 in 50,000. The hallmark feature of CVID is the lack of specific antibodies against pathogens and the most common symptoms include severe, recurrent or sometime chronic infections, mainly of respiratory and gastrointestinal tracts, increased incidence of autoimmunity, and neoplastic disorders. The primary objective of this study is to identify potential TNFRSF13B (TACI) mutations (novel and/or existing) in the local CVID population.